PO.TB10.09 · 肿瘤生物学
FcRn 和巨胞饮作用促进肿瘤相关巨噬细胞摄取白蛋白
FcRn and macropinocytosis promote albumin uptake in tumor-associated macrophages
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:血清白蛋白是血清中含量最丰富、循环时间最长的蛋白质,已被成功用作癌症治疗的药物递送载体。我们此前已证明,白蛋白在肿瘤中高水平蓄积,包括未分化甲状腺癌(ATC)、胰腺癌和前列腺癌。癌细胞中由癌基因驱动的巨胞饮作用在白蛋白摄取中发挥主要作用。然而,对于肿瘤浸润免疫细胞中白蛋白的摄取水平及其蓄积机制,人们知之甚少。我们假设肿瘤浸润免疫细胞,尤其是肿瘤相关巨噬细胞(TAM),可通过巨胞饮作用和 FcRn 介导的内吞作用高效摄取白蛋白。
方法:我们通过荧光反射成像评估小鼠血清白蛋白的体内摄取情况,并通过流式细胞术评估免疫功能健全的 ATC TBP3743(Braf V600E p53 -/-,B6129SF1/J 小鼠)和黑色素瘤 YUMM1.7(Braf V600E/wt Pten -/- Cdkn2 -/-,C57BL/6J 小鼠)模型中的细胞白蛋白摄取。我们进一步在新生 Fc 受体(FcRn)缺陷和 caveolin 1(Cav1)缺陷小鼠中鉴定肿瘤和细胞的白蛋白摄取。在从野生型、FcRn -/-(Fcgrt -/-)和 Cav1 -/- 小鼠分离的骨髓来源巨噬细胞(BMDM)中定量体外血清白蛋白的细胞摄取。我们进一步用 Na+/H+ 交换体(NHE)抑制剂 5-(N-乙基-N-异丙基)阿米洛利(EIPA)处理 BMDM 以阻断巨胞饮作用,并用岩藻多糖阻断清道夫受体介导的内吞作用。
结果:静脉给予白蛋白 24 小时后,小鼠 TBP3743 肿瘤和 YUMM1.7 肿瘤分别以 9%ID/g(每克组织的注射剂量百分比)和 11%ID/g 蓄积血清白蛋白。尽管 TAM 在 ATC 肿瘤中仅占细胞的 4%、在黑色素瘤肿瘤中占 5%,但它们蓄积了肿瘤微环境中总荧光白蛋白中不成比例的高比例(分别为 22% 和 19%)。Cav1 -/- 和 FcRn -/- 小鼠肿瘤中蓄积的白蛋白分别仅为野生型小鼠中所观察到的摄取量的 10% 和 29%。Cav1 -/- 和 FcRn -/- 宿主中 TAM 内血清白蛋白的平均荧光强度分别为野生型宿主水平的 78% 和 32%。体外 Cav1 -/- 和 FcRn -/- BMDM 蓄积的白蛋白分别为野生型 BMDM 的 107% 和 44%。EIPA 使野生型、Cav1 -/- 和 FcRn -/- BMDM 的白蛋白摄取分别减少 68%、76% 和 84%。岩藻多糖未改变任一种 BMDM 的白蛋白摄取。
结论:在 ATC 和黑色素瘤肿瘤微环境的各类细胞中,TAM 在单细胞水平上表现出最高的白蛋白摄取。重要的是,我们的数据表明,巨胞饮作用和 FcRn 介导的内吞作用是 TAM 摄取白蛋白的原因。因此,白蛋白通过 FcRn 和巨胞饮作用高效蓄积于 TAM 中,为将白蛋白作为 TAM 靶向治疗药物的递送载体提供了依据。
查看英文原文 English abstract
Background: Serum albumin, the most abundant and long-circulating protein in serum, has been successfully used as a drug delivery vehicle for cancer therapy. We have previously demonstrated that albumin accumulates at high levels in tumors, including anaplastic thyroid cancer (ATC), pancreatic cancer and prostate cancer. Oncogene-driven macropinocytosis in cancer cells plays a major role in albumin uptake. However, little is known about the level of albumin uptake and the mechanisms that contribute to its accumulation in tumor-infiltrating immune cells. We hypothesized that tumor-infiltrating immune cells, particularly tumor-associated macrophages (TAMs), efficiently take up albumin via macropinocytosis and FcRn-mediated endocytosis.
Methods: We assessed the in vivo uptake of mouse serum albumin by fluorescent reflectance imaging, and cellular albumin uptake by flow cytometry in the immunocompetent ATC TBP3743 ( Braf V600E p53 -/- ) in B6129SF1/J mice and melanoma YUMM1.7 ( Braf V600E/wt Pten -/- Cdkn2 -/- ) in C57BL/6J mice. We further identified tumor and cellular albumin uptake in neonatal Fc receptor (FcRn)- and caveolin 1 (Cav1)-deficient mice. In vitro cellular uptake of serum albumin was quantified in bone marrow-derived macrophages (BMDM) isolated from wildtype, FcRn -/- ( Fcgrt -/- ) and Cav1 -/- mice. We further treated BMDM with Na+/H+ exchanger (NHE) inhibitor 5-(N-ethyl-N-isopropyl)amiloride (EIPA) to block macropinocytosis, and fucoidan to block scavenger receptor-mediated endocytosis.
Results: TBP3743 tumors and YUMM1.7 tumors accumulated serum albumin at 9%ID/g (% injected dose per gram tissue) and 11%ID/g, respectively, in mice 24 hrs after intravenous albumin administration. Although TAMs comprised only 4% of cells in ATC tumors and 5% in melanoma tumors, they accumulated a disproportionately high proportion (22% and 19%, respectively) of total fluorescent albumin in the tumor microenvironment. Tumors in Cav1 -/- and FcRn -/- mice accumulated only 10% and 29%, respectively, of the albumin uptake observed in wildtype mice. The mean fluorescence intensity of the serum albumin in TAMs in Cav1 -/- and FcRn -/- hosts was 78%and 32% of the level in wildtype hosts. In vitro Cav1 -/- and FcRn -/- BMDM accumulated albumin 107% and 44% of wildtype BMDM. EIPA reduced albumin uptake by 68%, 76% and 84% in wildtype, Cav1 -/- and FcRn -/- BMDM. Fucoidan didn't alter albumin uptake in either BMDM.
Conclusion: TAMs exhibit the highest albumin uptake, on a per-cell basis, among cells within ATC and melanoma tumor microenvironments. Importantly, our data show that macropinocytosis and FcRn-mediated endocytosis are responsible for albumin uptake in TAMs. Thus, albumin accumulates efficiently in TAMs via FcRn and macropinocytosis, providing rationale for albumin as a drug delivery vehicle for TAM-targeted therapeutics.
利益披露 Disclosure
H. Hu, None..
X. Ge, None.